ClinicalTrials.gg

Program

casdatifan

Also written as “Casdatifan” and “AB521”.

Its studies are mostly in Carcinoma, Renal Cell · Clear-cell metastatic renal cell carcinoma, led by 3 companies.

Furthest: phase 3, since Jun 2, 20259 company-led studies, 4 open or runningNext primary completion: Jan 29, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Arcus Biosciences73 open or runningphase 3since Jun 2, 2025Nov 2, 2021May 2027phase 1 · NCT07751250
AstraZeneca11 open or runningphase 1since May 23, 2025May 23, 2025Jan 29, 2027phase 1 · NCT07000149
Exelixis10 open or runningphase 1since Dec 19, 2023Dec 19, 2023none ahead

Also a collaborator on its studies: summit-therapeutics, LG Chem and Otsuka.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 2, 2021First study: phase 1 study in Healthy ParticipantsNew to Arcus BiosciencesArcus Biosciences · NCT05117554 · 70 enrolled · Netherlands
  2. Sep 7, 2022Phase 1 study in Carcinoma, Renal CellArcus Biosciences · NCT05536141 · 512 planned · United States, Australia, South Korea and more
  3. Aug 14, 2023Phase 1 study in Healthy ParticipantsArcus Biosciences · NCT05999513 · 24 enrolled · United States
  4. Dec 19, 2023Exelixis's first study: phase 1 study in Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid TumorsNew to ExelixisExelixis · NCT06191796 · 25 enrolled · United States
  5. Mar 27, 2025Phase 1 study in Healthy ParticipantsArcus Biosciences · NCT06919991 · 14 enrolled · United States
  6. May 23, 2025AstraZeneca's first study: phase 1 study in Diabetes Mellitus, Insulin-Dependent, 12New to AstraZenecaAstraZeneca · NCT07000149 · 9 enrolled · Australia, South Korea
  7. Jun 2, 2025Phase 3 study in Clear-cell metastatic renal cell carcinomaArcus Biosciences · NCT07011719 · 720 planned · United States, Argentina, Australia and more
  8. Jun 8, 2026Phase 1 study in Healthy ParticipantsArcus Biosciences · NCT07641881 · 24 enrolled · United States
  9. Aug 3, 2026Phase 1 study in Healthy ParticipantsArcus Biosciences · NCT07751250 · 16 planned · United States

Ahead

  1. Jan 29, 2027Primary completion: phase 1 study in Diabetes Mellitus, Insulin-Dependent, 12AstraZeneca · NCT07000149
  2. May 2027Primary completion: phase 1 study in Healthy ParticipantsArcus Biosciences · NCT07751250
  3. Apr 2028Primary completion: phase 3 study in Clear-cell metastatic renal cell carcinomaArcus Biosciences · NCT07011719
  4. Mar 2029Primary completion: phase 1 study in Carcinoma, Renal CellArcus Biosciences · NCT05536141

TargetBeta

EPAS1 →read by rule
“This is a single-institution, pilot study of oral casdatifan, a selective HIF-2α inhibitor, in patients with metastatic clear cell renal cell carcinoma refractory to prior IO- and VEGF-based therapies.”study text, by rule · the study

Other programs on EPAS1

ProgramCompanyFurthest phaseStudies
belzutifanruleMerckphase 324

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07751250Healthy Participants · United States1RecruitingArcus BiosciencesMay 202716
NCT07641881Healthy Participants · United States1CompletedArcus BiosciencesJul 3, 202624
NCT07011719Clear-cell metastatic renal cell carcinoma · United States, Argentina, Australia and more3RecruitingArcus BiosciencesApr 2028720
NCT07000149Diabetes Mellitus, Insulin-Dependent, 12 · Australia, South Korea1Active, not recruitingAstraZenecaJan 29, 20279
NCT06919991Healthy Participants · United States1CompletedArcus BiosciencesOct 18, 202514
NCT06191796Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors · United States1TerminatedExelixisMay 12, 202525
NCT05999513Healthy Participants · United States1CompletedArcus BiosciencesOct 31, 202324
NCT05536141Carcinoma, Renal Cell · United States, Australia, South Korea and more1RecruitingArcus BiosciencesMar 2029512
NCT05117554Healthy Participants · Netherlands1CompletedArcus BiosciencesFeb 17, 202370

How it is read

Names in the registry

  • “Casdatifan”, 6 entries
  • “casdatifan”, 2 entries
  • “AB521”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.